64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: Radiopharmaceuticals for PET of topoisomerase II expression in tumors

Journal of Nuclear Medicine

Volumn 47, Issue 12, 2006, Pages 2034-2041

  Wei, Lihui ^a   Easmon, Johnny ^b   Nagi, Ravneet K ^a   Muegge, Brian D ^a   Meyer, Laura A ^a   Lewis, Jason S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

64Cu; Small animal PET; Thiosemicarbazones; Topoisomerase II

Indexed keywords

ALCOHOL; COPPER 64; DNA TOPOISOMERASE (ATP HYDROLYSING); EPH 142; EPH 142 CU 64; EPH 143; EPH 143 CU 64; EPH 144; EPH 144 CU 64; EPH 270; EPH 270 CU 64; RADIOPHARMACEUTICAL AGENT; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FUSED HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG PURITY; DRUG UPTAKE; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIPOPHILICITY; MOUSE; NONHUMAN; PARTITION COEFFICIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; RADIOCHEMISTRY; RADIOISOTOPE DISTRIBUTION; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; GENE EXPRESSION; LEUKEMIA L 1210; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; DNA TOPOISOMERASES, TYPE II; FEMALE; GENE EXPRESSION; LEUKEMIA L1210; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES; TISSUE DISTRIBUTION;

EID: 34547144745     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. McCarthy DW, Bass LA, Cutler PD, et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol. 1999;26:351-358.
2. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
3. 62Cu-PTSM. J Nucl Med. 2000;41:309-314.
4. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957-980.
5. 4- methylthiosemicarbazone). Int J Rad Instrum B. 1987;14:59-61.
6. Taniuchi H, Fujibayashi Y, Yonekura Y, Konishi J, Yokoyama A. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med. 1997;38:1130-1134.
7. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott R. Evaluation of copper(II)-pyruvaldehyde bis(N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med. 1994;21:336-341.
8. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
9. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
10. 4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655-661.
11. 64Cu-ATSM) in vivo and in vitro in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
12. 4- methylthiosemicarbazone). J Nucl Med. 2002;43:1557-1569.
13. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
14. 4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci U S A. 2001;98:1206-1211.
15. 4-methylthiosemicarbazone) for prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. Cancer Res. 2002;62:445-449.
16. 4-methylthiosemicarbazone) using 2-deoxy-D-glucose. Cancer Res. 2003;63:5496-5504.
17. Larsen AK, Skladanowski A, Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res. 1996;2:229-239.
18. Larsen AK, Gobert C, Gilbert C, Markovits J, Bojanowski K, Skladanowski A. DNA topoisomerases as repair enzymes: mechanism(s) of action and regulation by p53. Acta Biochim Pol. 1998;45:535-544.
19. Heck MM, Hittleman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A. 1988;85:1086-1090.
20. Potmesil M, Hsiang Y-H, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA-cleavage and low levels of DNA topoisomerase-II. Cancer Res. 1988;48:3537-3543.
21. Heck MM, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J Cell Biol. 1986;103:2569-2581.
22. Hwang JL, Shyy SH, Chen AY, Juan CC, Whang-Peng J. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res. 1989;49:958-962.
23. Larsen AK, Escargueil AE, Skladanowski A. From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog Cell Cycle Res. 2003;5:295-300.
24. Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther. 2003;99:167-181.
25. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta. 1998;1400:121-137.
26. Doyle LA. Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol. 1994;34(suppl):S32-S40.
27. Robert J, Larsen AK. Drug resistance to topoisomerase II inhibitors. Biochimie. 1998;80:247-254.
28. Robson CN, Hoban PR, Harris AL, Hickson ID. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Cancer Res. 1987;47:1560-1565.
29. 4N- azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J Med Chem. 2001;44:2164-2171.
30. Easmon J, Puerstinger G, Roth T, et al. 2-Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: a novel class of antitumor agents. Int J Cancer. 2001;94:89-96.
31. Easmon J, Heinisch G, Holzer W, Rosenwirth B. Novel thiosemicarbazones derived from formyl- and acyldiazines: synthesis, effects on cell proliferation, and synergism with antiviral agents. J Med Chem. 1992;35:3288-3296.
32. Miller MC 3rd, Stineman CN, Vance JR, West DX, Hall IH. The cytotoxicity of copper(II) complexes of 2-acetyl-pyridyl-4N-substituted thiosemicarbazones. Anticancer Res. 1998;18:4131-4139.
33. Miller MC 3rd, Bastow KF, Stineman CN, et al. The cytotoxicity of 2-formyl and 2-acetyl-(6-picolyl)-4N-substituted thiosemicarbazones and their copper(II) complexes. Arch Pharm (Weinheim). 1998;331:121-127.
34. Chen J, Huang Y-W, Liu G, et al. The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2004;197:40-48.
35. Muller MT, Spitzner JR, DiDonato JA, Mehta VB, Tsutsui K, Tsutsui K. Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry. 1988;27:8369-8379.
36. Tai YC, Ruangma A, Rowland DJ, et al. Performance evaluation of the microPET Focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455-463.
37. Burden DA, Kingma PS, Frolich-Ammon SJ, et al. Topoisomerase II·etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem. 1996;271:29238-29244.
38. Hande K. Etoposide is a topo-II poison, stabilizing transient covalent bond with DNA and promoting degradation and apoptosis. Eur J Cancer. 1998;34:1514-1521.
39. Juenke JM, Holden JA. The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta. 1993;1216:191-196.
40. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer. 1997;75:1340-1346.
41. Carvalho PA, Chiu ML, Kronauge JF, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med. 1992;33:1516-1521.